CSPC Pharmaceutical Group Limited Overview
Pro stress-test →CSPC Pharmaceutical Group Limited is a leading Chinese pharmaceutical company listed on the Hong Kong Stock Exchange since 1994 and a constituent of the Hang Seng Index. The company manufactures and sells a diverse portfolio of pharmaceutical products across finished drugs, bulk products (vitamin C and antibiotics), and functional foods with operations spanning mainland China, Asia, Europe, and North America.
Strategic Profile
Pro stress-test →CSPC operates with innovative drugs as its core strategy, focusing on therapeutic areas including nervous system diseases, oncology, anti-infectives, and cardiovascular disease. The company maintains strong competitive positioning through vertical integration—manufacturing both active pharmaceutical ingredients (APIs) and formulations—and has established strategic collaborations including one with AstraZeneca for obesity and type 2 diabetes treatments.
Competitive Landscape
Pro stress-test →CSPC competes within China's pharmaceutical sector against other large domestic manufacturers and multinational companies. Key competitive advantages include extensive product portfolio spanning 1,000+ medications, vertical integration capabilities, and first-mover position among Chinese pharma in the Hang Seng Index. The company differentiates through therapeutic breadth and API manufacturing scale.
Industry Context
CSPC Pharmaceutical Group Limited operates in Pharmaceuticals & Biotechnology.
Key facts
Founded: 1992 · Headquarters: Shijiazhuang, China · Employees: 21,400 · Revenue: Not disclosed in latest data · Market cap: HKD 105.09B (~USD 13.4B)